NRC Health Revenue from Contract with Customer, Including Assessed Tax
NRC Health (NRC) reported Revenue from Contract with Customer, Including Assessed Tax of $32.47 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-11-08
- NRC Health revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $32.47M, a 8.17% increase year-over-year.
- NRC Health revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $31.41M, a 12.12% increase year-over-year.
- NRC Health revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $31.48M, a 1.49% increase year-over-year.
- NRC Health revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $30.64M, a 2.48% increase year-over-year.
- NRC Health revenue from contract with customer, including assessed tax for fiscal 2018 was $119.69M, a 1.81% increase from fiscal 2017.
- NRC Health revenue from contract with customer, including assessed tax for fiscal 2017 was $117.56M, a 7.47% increase from fiscal 2016.
- NRC Health revenue from contract with customer, including assessed tax for fiscal 2016 was $109.38M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2019-09-30 | $32.47M 10-Q · filed 2019-11-08 | $63.88M derived: sum of 2 quarters · filed 2019-11-08 | $95.36M 10-Q · filed 2019-11-08 | $126.00M derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | $31.41M 10-Q · filed 2019-08-08 | $62.89M 10-Q · filed 2019-08-08 | $93.53M derived: sum of 3 quarters · filed 2019-08-08 | $123.55M derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-03-31 | $31.48M 10-Q · filed 2019-05-08 | $62.12M derived: sum of 2 quarters · filed 2019-05-08 | $92.13M derived: sum of 3 quarters · filed 2019-11-08 | $120.15M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-12-31 | $30.64M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $60.65M derived: sum of 2 quarters · filed 2019-11-08 | $88.67M derived: sum of 3 quarters · filed 2019-11-08 | $119.69M 10-K · filed 2019-03-08 |
| 2018-09-30 | $30.01M 10-Q · filed 2019-11-08 | $58.03M derived: sum of 2 quarters · filed 2019-11-08 | $89.05M 10-Q · filed 2019-11-08 | $118.94M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $28.02M 10-Q · filed 2019-08-08 | $59.03M 10-Q · filed 2019-08-08 | $88.93M derived: sum of 3 quarters · filed 2019-08-08 | $117.88M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $31.02M 10-Q · filed 2019-05-08 | $60.91M derived: sum of 2 quarters · filed 2019-05-08 | $89.87M derived: sum of 3 quarters · filed 2019-05-08 | $118.30M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $29.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $58.85M derived: sum of 2 quarters · filed 2019-03-08 | $87.28M derived: sum of 3 quarters · filed 2019-03-08 | $117.56M 10-K · filed 2019-03-08 |
| 2017-09-30 | $28.95M 10-Q · filed 2018-11-08 | $57.39M derived: sum of 2 quarters · filed 2018-11-08 | $87.66M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $28.43M 10-Q · filed 2018-08-09 | $58.71M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $30.28M 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | $109.38M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |